Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, New York 10032, USA.
Ann Thorac Surg. 2012 Sep;94(3):974-81; discussion 981-2. doi: 10.1016/j.athoracsur.2012.04.097. Epub 2012 Jun 28.
An open thymectomy is a morbid procedure. If a minimally invasive thymectomy is performed without compromising the tenets of thymic surgery, it has the potential for decreasing morbidity and may offer similar clinical and oncologic results.
This is an institutional review board-approved, retrospective study of a single center's experience with both open (transsternal) and minimally invasive (video-assisted thoracoscopic surgery) thymectomy. Survival estimates and statistical comparisons were calculated using standard software.
From 2000 to 2011, 263 patients (93 men; median age, 49 years; interquartile range, 37 to 60 years) underwent thymectomy for indications including myasthenia gravis (n=139) and mediastinal mass (n=108). Seventy-seven thymectomies were performed by minimally invasive approach. Both groups were equally stratified by sex, body mass index, World Health Organization and Masaoka-Koga staging, incidence of myasthenia gravis, and comorbidities except hyperlipidemia and diabetes. The minimally invasive thymectomy cohort had significantly shorter hospital (p<0.01) and intensive care unit lengths of stay (p<0.01) and a lower estimated blood loss (p<0.01). There was an insignificant difference in postoperative cardiac and respiratory complication rates as well as vocal cord paralysis (p=0.60). There was no difference in terms of operative room times (p=0.88) or volume of blood products transfused (p=0.16) between the two groups. Higher estimated blood loss was associated with higher intensive care unit admission rates (p<0.01). All minimally invasive thymoma resections were complete, with negative margins.
Minimally invasive thymectomy is safe and achieves a comparable resection and postoperative complication profile when used selectively for all indications, including myasthenia gravis and small thymomas without vascular invasion.
开放性胸腺切除术是一种病态的手术。如果进行微创胸腺切除术而不影响胸腺手术的原则,它有可能降低发病率,并可能提供类似的临床和肿瘤学结果。
这是一项机构审查委员会批准的、单中心回顾性研究,涉及开放性(胸骨切开术)和微创(电视辅助胸腔镜手术)胸腺切除术。使用标准软件计算生存估计值和统计比较。
2000 年至 2011 年,263 例患者(93 例男性;中位年龄 49 岁;四分位间距 37 至 60 岁)因重症肌无力(n=139)和纵隔肿块(n=108)等指征接受了胸腺切除术。77 例胸腺切除术采用微创方法进行。两组在性别、体重指数、世界卫生组织和 Masaoka-Koga 分期、重症肌无力发生率和合并症(除高脂血症和糖尿病外)方面均相等。微创胸腺切除术组的住院(p<0.01)和重症监护病房(p<0.01)时间以及估计失血量(p<0.01)明显缩短。术后心脏和呼吸系统并发症以及声带麻痹的发生率(p=0.60)无显著差异。两组手术时间(p=0.88)或输血量(p=0.16)无差异。估计失血量较高与较高的重症监护病房入住率相关(p<0.01)。所有微创胸腺瘤切除术均为完整切除,切缘阴性。
微创胸腺切除术是安全的,在选择性用于所有指征(包括重症肌无力和无血管侵犯的小胸腺瘤)时,可达到类似的切除和术后并发症谱。